Another batch of volume purchase started: Valsartan, omeprazole, amoxicillin

Recently, on the official website of Jinhua Hospital of Zhejiang University, the announcement of the first batch of drugs to be purchased with quantity to be shortlisted enterprises published by Jinhua pharmaceutical purchasing Co., Ltd was posted to purchase 22 drugs with quantity (see the end of the article for details) According to the detailed rules for the implementation of drug volume purchasing of Jinhua pharmaceutical consumables with volume centralized purchasing alliance committee (the first batch), the price of drug enterprises is calculated according to the current medical insurance payment standard of Zhejiang Province, and the drug drop shall not be less than 10% In response to the notice on several policies and measures to further deepen the reform of the medical and health system, issued by the leading group of the State Council on deepening the reform of the medical and health system a day ago (29 days ago) - so far, with the amount of mercury in the procurement, the country and the local are water tight, just as the previous prediction, the country and the local are simultaneously making efforts to gather and fire Full open An era has come However, the core volume price linkage of volume purchase is common sense in many industries, including OTC purchase in the same pharmaceutical field - can you buy more and make it cheaper? How much do you want? The larger the quantity, the better the price But in the drug procurement of public hospitals, with the volume of procurement is now really implemented, and has become an industry event An industry expert, who is reluctant to give his name, told the author that this may be due to why the hospital still holds the medicine even after the zero mark up Huang Yong, marketing director of Yongjiang pharmaceutical industry, told cypress blue that the quantity and price of public hospitals had been on the Internet before For various reasons, the purchasing department had no commitment or could not fulfill the commitment, resulting in many disadvantages At present, the core of the successful implementation of national volume procurement is that the medical insurance is in charge of medical insurance payment and bidding, urging hospitals to report volume and implement indicators level by level Provincial hospitals and department doctors all have indicators It's easy to do with indicators The manufacturer is willing to take the initiative to cancel the intermediate link as soon as the indicators are implemented In fact, although the volume purchase price has plummeted, as long as it is the price confirmed by the manufacturer, there is still room for profit, but the agent or self-supporting team does not need it, and the clinical customer maintenance is basically gone The same is true for hospitals In the new procurement mode, the surplus of medical insurance payment is retained, the increased disposable income of hospitals such as medical service price is adjusted, the salary reform is promoted, and the enthusiasm of medical personnel is mobilized Li Zhixuan, director of China Tendering and bidding network, analyzed that the current pilot projects of national procurement have a large amount of pressure on the price, and the full implementation of volume procurement, the products within the medical insurance should be fully expanded and centralized procurement, and comprehensive price reduction, even though some manufacturers may escape from the catalogue in this process, but ultimately there is no way to escape, innovative drugs still have a long way to go in China, and pharmaceutical enterprises can now comprehensively improve their professionalism and quality Lower corporate costs In the era of post belt purchase, the industry concentration will be greatly improved An expert from a pharmaceutical policy research institute told cypress blue that the industry is now over scattered, and the cost and efficiency will be reduced and improved after the concentration is increased, which is a good thing for the industry Specifically speaking, Huang Yong believes that the country has significantly reduced drug prices through volume procurement, reduced medical insurance expenditures, and ensured that medical insurance funds do not go through the bottom Accelerate the consistency evaluation, reduce the drug price, promote the exit of low-energy enterprises, and optimize the industrial environment through supply side reform In the hospital port, we should strengthen the fight against medical commercial bribery, strengthen medical integrity, make efforts to rational clinical medication, reduce or eliminate the impact of customer maintenance, so as to reduce the number of employees, improve the professional quality of the stock personnel, and directly improve the business level of the enterprise In the future, production capacity enterprises will survive by production capacity advantages, such as Huahai; R & D enterprises will survive by patented products of new compounds, such as Hengrui However, some analysts believe that the positive significance of volume purchase is obvious to all, but it may take time for investors to understand the policy and affect their enthusiasm in the short term The other three purchase rules may also affect the input of other pharmaceutical companies to the consistency evaluation In fact, the biggest conflict with volume purchasing is the national price linkage At present, enterprises are required to declare the prices of other provinces in most of the provinces, and choose one price as their own online price Some provinces require the lowest price in China and the lowest price in ten provinces However, in the purchase mode of quantity based purchase and quantity price linkage, the prices obtained by each province and purchase alliance through negotiation are likely to be different In this way, the price linkage is meaningless and can be used as a reference for negotiation, but the specific negotiation should be based on the usage, otherwise it will affect the confidence of drug companies in price reduction If there is a link between quantity and price, price linkage may not be necessary In addition, with the in-depth promotion of volume procurement, it will have an obvious impact on drug research and development, hospital promotion, drug enterprise compliance, intensified business circulation shuffle, and acceleration of industry M & A As for whether this is a gradual process or an immediate effect, there may be an answer immediately Attachment: